"Clínica de Hematologia e Oncologia - consultas, exames, tratamentos de quimioterapia, implante de cateter PICC e atendimentos complementares de outras especialidades como Reumatologia e Radiologia Intervencionista."

During the past decade, Instituto Joinvilense de Hematologia E Oncologia conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Joinvilense de Hematologia E Oncologia" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Joinvilense de Hematologia E Oncologia" are "Multiple Myeloma" (3 trials), "Autologous Stem Cell Transplant" (1 trials), "Castration-Resistant Prostatic Cancer" (1 trials), "Metastatic Prostate Cancer" (1 trials) and "Metastatic Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Instituto Joinvilense de Hematologia E Oncologia" in a lesser frequency.

Most popular intervention types in "Instituto Joinvilense de Hematologia E Oncologia" are "Drug" (8 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Abiraterone Acetate" (1 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Carboplatin" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Joinvilense de Hematologia E Oncologia" are 7 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Joinvilense de Hematologia E Oncologia". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Instituto Joinvilense de Hematologia E Oncologia, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Joinvilense de Hematologia E Oncologia, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Instituto Joinvilense de Hematologia E Oncologia has several departments that took part in Clinical trials: "Instituto Joinvilense de Hematologia e Oncologia Ltda - Centro de Hematologia e Oncologia" - 2 trials